Nanocellulose as a natural source for groundbreaking applications in materials science: Todays state

Nanocelluloses are natural materials with at least one dimension in the nano-scale. They combine important cellulose properties with the features of nanomaterials and open new horizons for materials science and its applications. The field of nanocellulose materials is subdivided into three domains: biotechnologically produced bacterial nanocellulose hydrogels, mechanically delaminated cellulose nanofibers, and hydrolytically extracted cellulose nanocrystals. This review article describes todays state regarding the production, structural details, physicochemical properties, and innovative applications of these nanocelluloses. Promising technical applications including gels/foams, thickeners/stabilizers as well as reinforcing agents have been proposed and research from last five years indicates new potential for groundbreaking innovations in the areas of cosmetic products, wound dressings, drug carriers, medical implants, tissue engineering, food and composites. The current state of worldwide commercialization and the challenge of reducing nanocellulose production costs are also discussed.Dana Kralisch and Dagmar Fischer gratefully acknowledge the Free State of Thuringia and the European Social Fund (2016 FGR 0045) for funding. Dagmar Fischer would like to thank Yvette Pötzinger and Berit Karl for the excellent editorial support. Dieter Klemm, Friederike Kramer and Katrin Petzold-Welcke are grateful for the support by the Federal Ministry of Economic Affairs and Energy, ZIM (KF2748903MF4 and KF2386003MF3). Thanks are due to the employees of Jenpolymer Materials Ltd. & Co. KG and the Polymet Jena Association, especially Priv.-Doz. Dr. Wolfgang Fried, and Prof. Dr. Raimund W. Kinne, Experimental Rheumatology Unit, Department of Orthopedics, Jena University Hospital, Germany as well as to Dr. Detlef Gorski and Elke Langhammer, SuraChemicals GmbH, Jena, Germany for effective and helpful cooperation and stimulating interaction. Dieter Klemm and Friederike Kramer would like to thank Katharina Horn for the excellent editorial support. Miguel Gama acknowledges the funding from QREN (“Quadro de Referência Estratégica Nacional”) through the BioTecNorte operation (NORTE-01-0145-FEDER-000004) funded by the European Regional Development Fund under the scope of Norte2020-Programa Operacional Regional do Norte. Tom Lindström acknowledges RISE Bioeconomy for support and permission to publish. Emily Cranston and Stephanie Kedzior are thankful for funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) in the form of a Discovery Grant (RGPIN 402329) and PGSD graduate student scholarship, as well as support from the Faculty of Engineering at McMaster University.info:eu-repo/semantics/publishedVersio

EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients

Background Graft rejection and chronic CNI toxicity remain obstacles to organ transplant success. Current formulations of tacrolimus, such as Prograf® and Advagraf™, exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability. As dosing non-compliance can result in graft rejection, the once daily formulation of tacrolimus, Advagraf™, was developed (vs 2x/day Prograf®). Benefits of Advagraf™ are counterbalanced by delayed achievement of therapeutic trough levels and need for up to 50% higher doses to maintain Prograf®-equivalent troughs. Envarsus® is also a prolonged-release once-daily tacrolimus formulation, developed using MeltDose™ drug-delivery technology to increase drug bioavailability; improved bioavailability results in low patient drug absorption variability and less pronounced peak-to-trough fluctuations. In phase III de novo kidney transplant studies, Envarsus® proved non-inferior to twice-daily tacrolimus; however, no phase IV studies show superiority of Envarsus® vs Advagraf™ in de novo liver transplant (LTx) recipients. Methods The EnGraft compares bioavailability and tests superiority of Envarsus® (test arm) versus Advagraf™ (comparator arm) in de novo LTx recipients. A total of 268 patients from 15 German transplant centres will be randomised 1:1 within 14 days post-LTx. The primary endpoint is dose-normalised trough level (C/D ratio) measured 12 weeks after randomisation. Secondary endpoints include the number of dose adjustments, time to reach first defined trough level and incidence of graft rejections. Additionally, clinical and laboratory parameters will be assessed over a 3-year period. Discussion C/D ratio is an estimate for tacrolimus bioavailability. Improving bioavailability and increasing C/D ratio using Envarsus could reduce renal dysfunction and other tacrolimus-related toxicities; previous trials have shown that a higher C/D ratio (i.e. slower tacrolimus metabolism) is not only associated with improved renal function but also linked to reduced neurotoxic side effects. A higher C/D ratio could improve clinical outcomes for LTx recipients; EnGraft has begun, with one third of patients recruited by January 2022

Gardens, Japanese: Nara, Japan [002]

Photograph (detail) of roof of tea house, Nara, JapanTea house roof with moon-viewing window, Nara, Japan

Validation of the FEW16 questionnaire for the assessment of physical well-being in patients with heart failure with reduced ejection fraction: results from the CIBIS-ELD study

Tahirović E, Lashki DJ, Trippel TD, et al. Validation of the FEW16 questionnaire for the assessment of physical well-being in patients with heart failure with reduced ejection fraction: results from the CIBIS-ELD study. ESC Heart Failure. 2015;2(3):194-203